A founder of the Company in 2000, he has held the position of Chair of the Board of Directors since then. He earned his Ph.D. in Biochemistry from the University of Barcelona, and has completed various programs on finance and negotiation. He also completed the Senior Management Program (PADE) at IESE in 2005. In recent years, he has been a member of the board of several biotechnology companies, such as: ONCNOSIS PHARMA AIE, NINFAS AIE, ORYCAMB-PROJECT AIE, GEADIG-PHARMA AIE, NEUROTEC PHARMA, S.L., PALOBIOFARMA, S.L. He has been a member of the Advisory Board of NEUROSCIENCES TECHNOLOGIES and is a member of MENDELION, S.L. He is ORYZON’s representative on the Governing Board of the Asociación Española de Bioempresas (ASEBIO), of which ORYZON was a member from 2005 until December 2019; during the period between 2009 and 2011, ORYZON held the position of Vice Chair of such Governing Board. He is also a member of the Board of Directors of INVEREADY SEED CAPITAL and of INVEREADY BIOTECH since September 7, 2008 and October 10, 2012, respectively.
First appointment as Director: 20 february 2002
Re-election: 02 september 2020
Company shares: CNMV